Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Principal Accounting Officer | June 21, 2021 | June 23, 2021 |
| Prime Medicine, Inc.PRME · Entity 5281 | See Remarks | February 23, 2026 | February 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 21, 2021 · Filed June 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-06-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-06-21 · Exercise / conversion · Acquired 1,777 · Balance 1,777 F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Row 2 · 2021-06-21 · Sale · Disposed 1,777 · Balance 0 F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.51 · Expires 2030-02-14 | Direct | 3,555 |
Reported balance
After 2021-06-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-06-21 · Exercise / conversion · Disposed 1,777 · Balance 3,555 F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3: This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Prime Medicine, Inc.
Report date February 23, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.34 · Expires 2036-02-23 | Direct | 140,000 |
Reported balance
After 2026-02-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-23 · Grant · Acquired 140,000 · Balance 140,000 F1: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 23, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 23, 2026, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2026 Filed Feb 24, 2026 21:58 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0001628280-26-011181 · wk-form4_1771970281.xml · derivative · entry 1 Alenson Carman · CIK 0001688865 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2036-02-23 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 23, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:42 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 90,498 | Not disclosed Strike: $4.04 | Not disclosed |
DisclosureSEC source: 0001894562-25-000042 · wk-form4_1754440946.xml · derivative · entry 8 Alenson Carman · CIK 0001688865 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,498 Underlying: Common Stock · 90,498 shares Expires 2034-02-21 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:42 UTC | Prime Medicine, Inc. PRME · Entity 5281 | Disposition to issuerStock Option (right to buy) · Derivative | 90,498 | Not disclosed Strike: $8.49 | Not disclosed |
DisclosureSEC source: 0001894562-25-000042 · wk-form4_1754440946.xml · derivative · entry 7 Alenson Carman · CIK 0001688865 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,498 shares Expires 2034-02-21 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:42 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 6,254 | Not disclosed Strike: $4.04 | Not disclosed |
DisclosureSEC source: 0001894562-25-000042 · wk-form4_1754440946.xml · derivative · entry 6 Alenson Carman · CIK 0001688865 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,254 Underlying: Common Stock · 6,254 shares Expires 2033-04-18 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:42 UTC | Prime Medicine, Inc. PRME · Entity 5281 | Disposition to issuerStock Option (right to buy) · Derivative | 6,254 | Not disclosed Strike: $13.63 | Not disclosed |
DisclosureSEC source: 0001894562-25-000042 · wk-form4_1754440946.xml · derivative · entry 5 Alenson Carman · CIK 0001688865 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,254 shares Expires 2033-04-18 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:42 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 90,498 | Not disclosed Strike: $4.04 | Not disclosed |
DisclosureSEC source: 0001894562-25-000042 · wk-form4_1754440946.xml · derivative · entry 4 Alenson Carman · CIK 0001688865 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,498 Underlying: Common Stock · 90,498 shares Expires 2033-03-31 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:42 UTC | Prime Medicine, Inc. PRME · Entity 5281 | Disposition to issuerStock Option (right to buy) · Derivative | 90,498 | Not disclosed Strike: $12.30 | Not disclosed |
DisclosureSEC source: 0001894562-25-000042 · wk-form4_1754440946.xml · derivative · entry 3 Alenson Carman · CIK 0001688865 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,498 shares Expires 2033-03-31 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:42 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 16,083 | Not disclosed Strike: $4.04 | Not disclosed |
DisclosureSEC source: 0001894562-25-000042 · wk-form4_1754440946.xml · derivative · entry 2 Alenson Carman · CIK 0001688865 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,083 Underlying: Common Stock · 16,083 shares Expires 2032-01-24 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:42 UTC | Prime Medicine, Inc. PRME · Entity 5281 | Disposition to issuerStock Option (right to buy) · Derivative | 16,083 | Not disclosed Strike: $10.92 | Not disclosed |
DisclosureSEC source: 0001894562-25-000042 · wk-form4_1754440946.xml · derivative · entry 1 Alenson Carman · CIK 0001688865 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,083 shares Expires 2032-01-24 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:18 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 90,500 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001894562-25-000012 · wk-form4_1741051100.xml · derivative · entry 1 Alenson Carman · CIK 0001688865 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,500 Underlying: Common Stock · 90,500 shares Expires 2035-02-27 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 27, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:01 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 90,498 | $0.00 Strike: $8.49 | $0.00 |
DisclosureSEC source: 0001894562-24-000010 · wk-form4_1708725660.xml · derivative · entry 1 Alenson Carman · CIK 0001688865 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,498 Underlying: Common Stock · 90,498 shares Expires 2034-02-21 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 21, 2024, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 20:28 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 6,254 | $0.00 Strike: $13.63 | $0.00 |
DisclosureSEC source: 0001894562-23-000010 · wf-form4_168202248714996.xml · derivative · entry 1 Alenson Carman · CIK 0001688865 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,254 Underlying: Common Stock · 6,254 shares Expires 2033-04-18 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 31, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:22 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 90,498 | $0.00 Strike: $12.30 | $0.00 |
DisclosureSEC source: 0001894562-23-000001 · wf-form4_168065412225046.xml · derivative · entry 1 Alenson Carman · CIK 0001688865 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,498 Underlying: Common Stock · 90,498 shares Expires 2033-03-31 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 31, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 17:28 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionStock option (right to buy) · Derivative | 1,777 | $0.00 Strike: $51.51 | $0.00 |
DisclosureSEC source: 0001439222-21-000060 · wf-form4_162448370684332.xml · derivative · entry 3 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,555 Underlying: Common stock · 1,777 shares Expires 2030-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 17:28 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,777 | $61.61 | $109,480.97 |
DisclosureSEC source: 0001439222-21-000060 · wf-form4_162448370684332.xml · nonDerivative · entry 2 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 17:28 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,777 | $51.51 | $91,533.27 |
DisclosureSEC source: 0001439222-21-000060 · wf-form4_162448370684332.xml · nonDerivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 16:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 1,118 | $55.89 | $62,485.02 |
DisclosureSEC source: 0001439222-21-000035 · wf-form4_161894939327254.xml · nonDerivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 16:33 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 991 | $54.00 | $53,514.00 |
DisclosureSEC source: 0001439222-21-000034 · wf-form4_161860518490311.xml · nonDerivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,118 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 314 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 692 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000021 · wf-form4_161420111004318.xml · derivative · entry 3 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691 Underlying: Common stock · 692 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 199 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000021 · wf-form4_161420111004318.xml · nonDerivative · entry 2 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,795 Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 692 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000021 · wf-form4_161420111004318.xml · nonDerivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 16:13 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 790 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000010 · wf-form4_161359638023953.xml · derivative · entry 5 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 16,2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. F3 · derivative.expiration_date: The restricted stock units were granted on February 16,2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 16:13 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 561 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000010 · wf-form4_161359638023953.xml · nonDerivative · entry 3 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,302 Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 16:13 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 790 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000010 · wf-form4_161359638023953.xml · nonDerivative · entry 2 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2021 Filed Feb 17, 2021 16:13 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 889 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000010 · wf-form4_161359638023953.xml · derivative · entry 4 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,777 Underlying: Common stock · 889 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 14, 2021 Filed Feb 17, 2021 16:13 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 889 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000010 · wf-form4_161359638023953.xml · nonDerivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 16:22 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 2,961 | $0.00 Strike: $56.68 | $0.00 |
DisclosureSEC source: 0001439222-21-000003 · wf-form4_161316487303183.xml · derivative · entry 2 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,961 Underlying: Common stock · 2,961 shares Expires 2031-02-10 F3 · derivative.exercise_date: This option was granted on February 10, 2021. The shares underlying this option vest as to 25% of the underlying shares on February 10, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 16:22 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 5,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000003 · wf-form4_161316487303183.xml · derivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,922 Underlying: Common stock · 5,922 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 16:38 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000063 · wf-form4_160313988956166.xml · derivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on October 15, 2020. The shares underlying the restricted stock units will vest in full on October 15, 2022. F2 · derivative.expiration_date: The restricted stock units were granted on October 15, 2020. The shares underlying the restricted stock units will vest in full on October 15, 2022. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 16:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 250 | $39.93 | $9,982.50 |
DisclosureSEC source: 0001439222-20-000061 · wf-form4_159925103182387.xml · nonDerivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: Reflects shares purchased through the Company's employee stock purchase plan. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 17:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 345 | $47.30 | $16,318.50 |
DisclosureSEC source: 0001439222-20-000027 · wf-form4_158335970016750.xml · nonDerivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: Reflects shares purchased through the Company's employee stock purchase plan. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 16:17 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 472 | $47.12 | $22,240.64 |
DisclosureSEC source: 0001439222-20-000025 · wf-form4_158292460758493.xml · nonDerivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 16:23 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 219 | $48.66 | $10,656.54 |
DisclosureSEC source: 0001439222-20-000021 · wf-form4_158266581146076.xml · nonDerivative · entry 2 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 656 Read SEC document |
| February 22, 2020 Filed Feb 25, 2020 16:23 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 691 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000021 · wf-form4_158266581146076.xml · derivative · entry 3 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,383 Underlying: Common stock · 691 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 22, 2020 Filed Feb 25, 2020 16:23 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 691 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000021 · wf-form4_158266581146076.xml · nonDerivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 16:02 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,427 | $53.37 | $129,528.99 |
DisclosureSEC source: 0001439222-20-000020 · wf-form4_158257813545803.xml · nonDerivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $53.25 to $53.58. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 16:55 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 1,163 | $52.01 | $60,487.63 |
DisclosureSEC source: 0001439222-20-000019 · wf-form4_158214930367652.xml · nonDerivative · entry 3 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,611 Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 16:55 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000019 · wf-form4_158214930367652.xml · derivative · entry 8 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F6 · derivative.exercise_date: All of the restricted stock units will vest on February 16, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F6 · derivative.expiration_date: All of the restricted stock units will vest on February 16, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 16:55 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 790 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000019 · wf-form4_158214930367652.xml · derivative · entry 7 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 790 Underlying: Common stock · 790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F5 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 16:55 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000019 · wf-form4_158214930367652.xml · nonDerivative · entry 2 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 16:55 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000019 · wf-form4_158214930367652.xml · nonDerivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 16:55 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 5,332 | $0.00 Strike: $51.51 | $0.00 |
DisclosureSEC source: 0001439222-20-000019 · wf-form4_158214930367652.xml · derivative · entry 6 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,332 Underlying: Common stock · 5,332 shares Expires 2030-02-14 F4 · derivative.exercise_date: This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 16:55 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock unit · Derivative | 4,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000019 · wf-form4_158214930367652.xml · derivative · entry 5 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Underlying: Common stock · 4,800 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. The shares underlying the restricted stock units will vest in full on February 14, 2022. F3 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. The shares underlying the restricted stock units will vest in full on February 14, 2022. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 16:55 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 2,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000019 · wf-form4_158214930367652.xml · derivative · entry 4 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,666 Underlying: Common stock · 2,666 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. Beginning on February, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. Beginning on February, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| December 26, 2019 Filed Dec 30, 2019 16:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 2,950 | $50.09 | $147,765.50 |
DisclosureSEC source: 0001439222-19-000030 · wf-form4_157774008262318.xml · nonDerivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.04 to $50.58. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares purchased through the Company's employee stock purchase plan. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 16:21 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 2,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013515 · doc4.xml · derivative · entry 2 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,074 Underlying: Common stock · 2,074 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 16:21 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 8,295 | $0.00 Strike: $58.86 | $0.00 |
DisclosureSEC source: 0001209191-19-013515 · doc4.xml · derivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,295 Underlying: Common stock · 8,295 shares Expires 2029-02-22 F1 · derivative.exercise_date: This option was granted on February 22, 2019. The shares underlying this option vest as to 25% of the underlying shares on February 22, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 16:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-012942 · doc4.xml · derivative · entry 3 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: All of the restricted stock units vested on February 21, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: All of the restricted stock units vested on February 21, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 16:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 1,016 | $56.33 | $57,231.28 |
DisclosureSEC source: 0001209191-19-012942 · doc4.xml · nonDerivative · entry 2 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,796 Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 16:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-012942 · doc4.xml · nonDerivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.